Skip to content
Screener

Arvinas ARVN Total Equity

Total Equity at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$402.63M-10.0%
LON
LeonaBio, Inc.LONA
$49.3M+32.1%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$1.51B+55.4%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$487.28M+81.8%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$218.73M+875%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$323.98M+60.0%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$572.13M+18.3%
Enterprise value$493.43M+30.3%
P/S6.4×+5.1×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Arvinas’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 5:18 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033669
(dollars and shares in millions, except per share amounts)March 31,2026December 31,2025
Preferred stock, $0.001 par value, zero shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Common stock, $0.001 par value; 74.5 shares issued and 64.5 shares outstanding as of March 31, 2026, and 73.5 shares issued and 63.5 outstanding as of December 31, 20250.10.1
Accumulated deficit(1,670.0)(1,612.4)
Additional paid-in capital2,149.02,136.9
Accumulated other comprehensive (loss) income(0.4)1.2
Treasury Stock, at cost (10.0 shares as of March 31, 2026 and December 31, 2025)(91.9)(91.9)
Total stockholders’ equity386.8433.9
Total liabilities and stockholders’ equity$647.5$717.9

Item 1. Financial Statements (Unaudited)

FAQ

What is Arvinas's total equity?
Arvinas (ARVN) reported total equity of $386.8M in Q1 2026.
How has Arvinas's total equity changed year-over-year?
Arvinas's total equity decreased by 41.4% year-over-year, from $660.1M to $386.8M.
What is the long-term trend for Arvinas's total equity?
Over 5 years (2020 to 2025), Arvinas's total equity has grown at a -7.5% compound annual growth rate (CAGR), from $642.2M to $433.9M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Arvinas's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude